Keynote Swiss Diagnostics Startup Day

Closing keynote to the annual innovation conference of Swiss Biolabs, Olten

Transcript

1. View Slide

2. Hannes Gassert
   Civic Entrepreneur
   Startup Value(s)?
   Keynote Swiss Biolabs, 2019/5/23
   

   View Slide

3. liip.ch
   wemakeit.com
   skim.com
   etoy.com
   liftconference.com
   opendata.ch
   powercoders.org
   sp-zuerich.ch
   crstl.io
   gassert.ch
   

   View Slide

4. A reflection on health innovation
   from an outsider, to you insiders
   Startup Value(s)?
   

   View Slide

5. Value?
   

   View Slide

6. Value?
   

   View Slide

7. Value?
   

   View Slide

8. «A business model describes the
   rationale of how an organization
   creates, delivers, and captures
   value.»
   Alex Osterwalder & Yves Pigneur, 2011
   

   View Slide

9. Quick survey, part 1:
   Who thinks health innovation
   is creating value?
   

   View Slide

10. Quick survey, part 2:
    Who thinks health innovation
    is working well?
    

    View Slide

11. «Hm.»
    Hannes Gassert, 2018
    

    View Slide

12. Tamy Glauser, Candidate for the Swiss National Council (GP, ZH)
    

    View Slide

13. View Slide

14. View Slide

15. View Slide

16. CONCLUSION?
    

    View Slide

17. View Slide

18. SCIENCE WINTER?
    Reproducibility crisis
    

    View Slide

19. PATENT WINTER?
    Intellectual property crisis
    

    View Slide

20. Startup Value(s)?
    

    View Slide

21. «Cui bono?»
    Seneca, 44 BCE
    

    View Slide

22. «Between 2000 and 2011, only 4%
    of newly approved products were
    for neglected diseases that affect
    middle and low-income countries.»
    Pedrique, B. et al (2013)
    Lancet Global Health, 1(6):e371-379
    

    View Slide

23. NORTH / SOUTH
    

    View Slide

24. View Slide

25. ED / PMS
    10x research on men’s
    issues vs. women’s issues
    

    View Slide

26. View Slide

27. PUBLIC / PRIVATE
    Public investment, private profit?
    

    View Slide

28. View Slide

29. «The current system for developing drugs
    incentivises high prices and delivers
    short-term returns to shareholders, rather
    than focusing on riskier, longer-term
    research which leads to critically needed
    therapeutic advances.»
    Mazzucato, M. et al (2018)
    The people’s prescription, UCL Institute for
    Innovation and Public Purpose Policy Report
    

    View Slide

30. QUESTION:
    How to transform the current
    financialized health innovation
    model to be more long-term and
    “mission-oriented”?
    

    View Slide

31. QUESTION:
    How to define the “purpose” of a
    broader model of health innovation
    based on public value and human
    rights?
    

    View Slide

32. QUESTION:
    What will your diagnostics startups
    contribute to a health system that
    benefits all?
    

    View Slide

33. Switzerland?
    

    View Slide

34. View Slide

35. Startup Value(s)?
    

    View Slide

36. Purpose over profits
    Trust over control
    Practice over theory
    Risk over safety
    Flexibility over strength
    Open over closed
    Compasses over maps
    

    View Slide

37. Startup Value(s)?
    

    View Slide

38. CREATE MORE
    VALUE THAN
    YOU CAPTURE.
    

    View Slide

39. Hannes Gassert
    @hannesgassert
    hg@crstl.ch
    Slides: http://liip.to/sbl19
    Merci.
    

    View Slide